메뉴 건너뛰기




Volumn 5, Issue 11, 2015, Pages

Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: An acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE RECEPTOR AGONIST; GLYCOSYLATED HEMOGLOBIN; LIPID; LIRAGLUTIDE; PANCREATIC ELASTASE; PLACEBO; SITAGLIPTIN; ANTIDIABETIC AGENT; INCRETIN; PEPTIDE; VENOM;

EID: 84956921354     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-009579     Document Type: Article
Times cited : (28)

References (63)
  • 1
    • 84867497463 scopus 로고    scopus 로고
    • KDOQI clinical practice guideline for diabetes and CKD: 2012 update
    • National Kidney Foundation.
    • National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis 2012;60: 850-86.
    • (2012) Am J Kidney Dis , vol.60 , pp. 850-886
  • 2
    • 84925489733 scopus 로고    scopus 로고
    • Management of hyperglycaemia in type 2 diabetes, 2015: A patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes
    • Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2015;58:429-42.
    • (2015) Diabetologia , vol.58 , pp. 429-442
    • Inzucchi, S.E.1    Bergenstal, R.M.2    Buse, J.B.3
  • 4
    • 84901768284 scopus 로고    scopus 로고
    • Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes
    • Holman RR, Sourij H, Califf RM. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet 2014;383:2008-17.
    • (2014) Lancet , vol.383 , pp. 2008-2017
    • Holman, R.R.1    Sourij, H.2    Califf, R.M.3
  • 5
    • 84970922145 scopus 로고    scopus 로고
    • http://www.safeguard-diabetes.org.
  • 6
    • 35748957503 scopus 로고    scopus 로고
    • The physiology of glucagon-like peptide 1
    • Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007;87:1409-39.
    • (2007) Physiol Rev , vol.87 , pp. 1409-1439
    • Holst, J.J.1
  • 7
    • 0037045845 scopus 로고    scopus 로고
    • Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: A parallel-group study
    • Zander M, Madsbad S, Madsen JL, et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359:824-30.
    • (2002) Lancet , vol.359 , pp. 824-830
    • Zander, M.1    Madsbad, S.2    Madsen, J.L.3
  • 8
    • 0022617246 scopus 로고
    • Reduced incretin effect in type 2 (non-insulin-dependent) diabetes
    • Nauck M, Stöckmann F, Ebert R, et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986;29:46-52.
    • (1986) Diabetologia , vol.29 , pp. 46-52
    • Nauck, M.1    Stöckmann, F.2    Ebert, R.3
  • 9
    • 67651173077 scopus 로고    scopus 로고
    • Incretin-based therapies for type 2 diabetes mellitus
    • Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009;5:262-9.
    • (2009) Nat Rev Endocrinol , vol.5 , pp. 262-269
    • Lovshin, J.A.1    Drucker, D.J.2
  • 10
    • 84897852105 scopus 로고    scopus 로고
    • GLP-1 receptor localization in monkey and human tissue: Novel distribution revealed with extensively validated monoclonal antibody
    • Pyke C, Heller RS, Kirk RK, et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 2014;155:1280-90.
    • (2014) Endocrinology , vol.155 , pp. 1280-1290
    • Pyke, C.1    Heller, R.S.2    Kirk, R.K.3
  • 11
    • 34250635159 scopus 로고    scopus 로고
    • GLP-1 receptor expression in human tumors and human normal tissues: Potential for in vivo targeting
    • Körner M, Stöckli M, Waser B, et al. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med 2007;48:736-43.
    • (2007) J Nucl Med , vol.48 , pp. 736-743
    • Körner, M.1    Stöckli, M.2    Waser, B.3
  • 12
    • 84873554686 scopus 로고    scopus 로고
    • Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: Systematic review and meta-analysis
    • pii: e001986
    • Robinson L, Holt T, Rees K. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open 2013;3:pii: e001986.
    • (2013) BMJ Open , vol.3
    • Robinson, L.1    Holt, T.2    Rees, K.3
  • 13
    • 84912523371 scopus 로고    scopus 로고
    • Dipeptidyl-peptidase-4 inhibitors and heart failure: Class effect substance-specific effect or chance effect?
    • Standl E, Erbach M, Schnell O. Dipeptidyl-peptidase-4 inhibitors and heart failure: class effect, substance-specific effect, or chance effect? Curr Treat Options Cardiovasc Med 2014;16:353.
    • (2014) Curr Treat Options Cardiovasc Med , vol.16 , pp. 353
    • Standl, E.1    Erbach, M.2    Schnell, O.3
  • 14
    • 61849088993 scopus 로고    scopus 로고
    • Exenatide-associated ischemic renal failure
    • Weise WJ, Sivanandy MS, Block CA, et al. Exenatide-associated ischemic renal failure. Diabetes Care 2009;32:e22-3.
    • (2009) Diabetes Care , vol.32 , pp. e22-e23
    • Weise, W.J.1    Sivanandy, M.S.2    Block, C.A.3
  • 15
    • 42949089442 scopus 로고    scopus 로고
    • Exenatide and rare adverse events
    • discussion 1971-2
    • Ahmad SR, Swann J. Exenatide and rare adverse events. N Engl J Med 2008;358:1970-1; discussion 1971-2.
    • (2008) N Engl J Med , vol.358 , pp. 1970-1971
    • Ahmad, S.R.1    Swann, J.2
  • 16
    • 84876063836 scopus 로고    scopus 로고
    • Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: A population-based matched case-control study
    • Singh S, Chang H-Y, Richards TM, et al. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med2013;173:534-9.
    • (2013) JAMA Intern Med , vol.173 , pp. 534-539
    • Singh, S.1    Chang, H.-Y.2    Richards, T.M.3
  • 17
    • 79959559653 scopus 로고    scopus 로고
    • Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
    • Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011; 141:150-6.
    • (2011) Gastroenterology , vol.141 , pp. 150-156
    • Elashoff, M.1    Matveyenko, A.V.2    Gier, B.3
  • 18
    • 84856877681 scopus 로고    scopus 로고
    • Resting heart rate is associated with cardiovascular and all-cause mortality after adjusting for inflammatory markers: The Copenhagen City Heart Study
    • Jensen MT, Marott JL, Allin KH, et al. Resting heart rate is associated with cardiovascular and all-cause mortality after adjusting for inflammatory markers: the Copenhagen City Heart Study. Eur J Prev Cardiol 2012;19:102-8.
    • (2012) Eur J Prev Cardiol , vol.19 , pp. 102-108
    • Jensen, M.T.1    Marott, J.L.2    Allin, K.H.3
  • 19
    • 0032714917 scopus 로고    scopus 로고
    • Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats
    • Barragán JM, Eng J, Rodríguez R, et al. Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats. Am J Physiol1999;277:E784-91.
    • (1999) Am J Physiol , vol.277 , pp. E784-E791
    • Barragán, J.M.1    Eng, J.2    Rodríguez, R.3
  • 20
    • 31144446219 scopus 로고    scopus 로고
    • Mesenteric vasoconstriction and hindquarters vasodilatation accompany the pressor actions of exendin-4 in conscious rats
    • Gardiner SM, March JE, Kemp PA, et al. Mesenteric vasoconstriction and hindquarters vasodilatation accompany the pressor actions of exendin-4 in conscious rats. J Pharmacol Exp Ther 2006;316:852-9.
    • (2006) J Pharmacol Exp Ther , vol.316 , pp. 852-859
    • Gardiner, S.M.1    March, J.E.2    Kemp, P.A.3
  • 21
    • 84867254999 scopus 로고    scopus 로고
    • Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and-independent actions
    • Shigeta T, Aoyama M, Bando YK, et al. Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and-independent actions. Circulation 2012;126:1838-51.
    • (2012) Circulation , vol.126 , pp. 1838-1851
    • Shigeta, T.1    Aoyama, M.2    Bando, Y.K.3
  • 22
    • 84862521094 scopus 로고    scopus 로고
    • Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: A double-blind, randomised controlled clinical trial of efficacy and safety
    • Nathanson D, Ullman B, Löfström U, et al. Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety. Diabetologia 2012;55:926-35.
    • (2012) Diabetologia , vol.55 , pp. 926-935
    • Nathanson, D.1    Ullman, B.2    Löfström, U.3
  • 23
    • 84883765959 scopus 로고    scopus 로고
    • Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
    • Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-26.
    • (2013) N Engl J Med , vol.369 , pp. 1317-1326
    • Scirica, B.M.1    Bhatt, D.L.2    Braunwald, E.3
  • 24
    • 84932636107 scopus 로고    scopus 로고
    • Increased risk of hospitalization for heart failure with newly prescribed dipeptidyl peptidase-4 inhibitors and pioglitazone using the Korean Health Insurance Claims Database
    • Suh S, Seo GH, Jung CH, et al. Increased risk of hospitalization for heart failure with newly prescribed dipeptidyl peptidase-4 inhibitors and pioglitazone using the Korean Health Insurance Claims Database. Diabetes Metab J 2015;39:247-52.
    • (2015) Diabetes Metab J , vol.39 , pp. 247-252
    • Suh, S.1    Seo, G.H.2    Ch, J.3
  • 25
    • 8544258807 scopus 로고    scopus 로고
    • Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease
    • Nyström T, Gutniak MK, Zhang Q, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004;287:E1209-15.
    • (2004) Am J Physiol Endocrinol Metab , vol.287 , pp. E1209-E1215
    • Nyström, T.1    Gutniak, M.K.2    Zhang, Q.3
  • 26
    • 79956119675 scopus 로고    scopus 로고
    • The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an 'endothelial resistance' to glucagon-like peptide 1 in diabetes
    • Ceriello A, Esposito K, Testa R, et al. The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an 'endothelial resistance' to glucagon-like peptide 1 in diabetes. Diabetes Care 2011;34:697-702.
    • (2011) Diabetes Care , vol.34 , pp. 697-702
    • Ceriello, A.1    Esposito, K.2    Testa, R.3
  • 27
    • 84893424204 scopus 로고    scopus 로고
    • A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis
    • Tashiro Y, Sato K, Watanabe T, et al. A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis. Peptides 2014;54:19-26.
    • (2014) Peptides , vol.54 , pp. 19-26
    • Tashiro, Y.1    Sato, K.2    Watanabe, T.3
  • 28
    • 84895762544 scopus 로고    scopus 로고
    • Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study
    • Rizzo M, Chandalia M, Patti AM, et al. Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study. Cardiovasc Diabetol 2014; 13:49.
    • (2014) Cardiovasc Diabetol , vol.13 , pp. 49
    • Rizzo, M.1    Chandalia, M.2    Patti, A.M.3
  • 29
    • 79955692561 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 (GLP-1), immediately prior to reperfusion, decreases neutrophil activation and reduces myocardial infarct size in rodents
    • Dokken BB, La Bonte LR, Davis-Gorman G, et al. Glucagon-like peptide-1 (GLP-1), immediately prior to reperfusion, decreases neutrophil activation and reduces myocardial infarct size in rodents. Horm Metab Res 2011;43:300-5.
    • (2011) Horm Metab Res , vol.43 , pp. 300-305
    • Dokken, B.B.1    La Bonte, L.R.2    Davis-Gorman, G.3
  • 30
    • 58949084130 scopus 로고    scopus 로고
    • Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury
    • Timmers L, Henriques JPS, de Kleijn DPV, et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 2009;53:501-10.
    • (2009) J Am Coll Cardiol , vol.53 , pp. 501-510
    • Timmers, L.1    Jps, H.2    De Kleijn DPV3
  • 31
    • 84923165949 scopus 로고    scopus 로고
    • Pre-treatment with glucagon-like Peptide-1 protects against ischemic left ventricular dysfunction and stunning without a detected difference in myocardial substrate utilization
    • McCormick LM, Hoole SP, White PA, et al. Pre-treatment with glucagon-like Peptide-1 protects against ischemic left ventricular dysfunction and stunning without a detected difference in myocardial substrate utilization. JACC Cardiovasc Interv 2015;8:292-301.
    • (2015) JACC Cardiovasc Interv , vol.8 , pp. 292-301
    • McCormick, L.M.1    Hoole, S.P.2    White, P.A.3
  • 32
    • 84860390563 scopus 로고    scopus 로고
    • A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans
    • Read PA, Hoole SP, White PA, et al. A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans. Circ Cardiovasc Interv 2011;4:266-72.
    • (2011) Circ Cardiovasc Interv , vol.4 , pp. 266-272
    • Read, P.A.1    Hoole, S.P.2    White, P.A.3
  • 33
    • 84863560602 scopus 로고    scopus 로고
    • Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction
    • Lønborg J, Vejlstrup N, Kelbæk H, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 2012;33:1491-9.
    • (2012) Eur Heart J , vol.33 , pp. 1491-1499
    • Lønborg, J.1    Vejlstrup, N.2    Kelbæk, H.3
  • 34
    • 84892743922 scopus 로고    scopus 로고
    • Effects of glucagon-like peptide-1 receptor agonists on renal function
    • Filippatos TD, Elisaf MS. Effects of glucagon-like peptide-1 receptor agonists on renal function. World J Diabetes 2013;4:190-201.
    • (2013) World J Diabetes , vol.4 , pp. 190-201
    • Filippatos, T.D.1    Elisaf, M.S.2
  • 35
    • 53349172746 scopus 로고    scopus 로고
    • Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use
    • Kao DP, Kohrt HE, Kugler J. Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use. Diabet Med 2008;25:1229-30.
    • (2008) Diabet Med , vol.25 , pp. 1229-1230
    • Kao, D.P.1    Kohrt, H.E.2    Kugler, J.3
  • 36
    • 84862777558 scopus 로고    scopus 로고
    • Exenatide and sitagliptin are not associated with increased risk of acute renal failure: A retrospective claims analysis
    • Pendergrass M, Fenton C, Haffner SM, et al. Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis. Diabetes Obes Metab 2012;14:596-600.
    • (2012) Diabetes Obes Metab , vol.14 , pp. 596-600
    • Pendergrass, M.1    Fenton, C.2    Haffner, S.M.3
  • 37
    • 0038202937 scopus 로고    scopus 로고
    • Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats
    • Yu M, Moreno C, Hoagland KM, et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens 2003;21:1125-35.
    • (2003) J Hypertens , vol.21 , pp. 1125-1135
    • Yu, M.1    Moreno, C.2    Hoagland, K.M.3
  • 38
    • 77955106477 scopus 로고    scopus 로고
    • The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats
    • Liu Q, Adams L, Broyde A, et al. The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats. Cardiovasc Diabetol 2010;9:32.
    • (2010) Cardiovasc Diabetol , vol.9 , pp. 32
    • Liu, Q.1    Adams, L.2    Broyde, A.3
  • 39
    • 34047205064 scopus 로고    scopus 로고
    • Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice
    • Park CW, Kim HW, Ko SH, et al. Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. J Am Soc Nephrol 2007;18:1227-38.
    • (2007) J Am Soc Nephrol , vol.18 , pp. 1227-1238
    • Park, C.W.1    Kim, H.W.2    Ko, S.H.3
  • 40
    • 84895072279 scopus 로고    scopus 로고
    • The gut-renal axis: Do incretin-based agents confer renoprotection in diabetes?
    • Muskiet MHA, Smits MM, Morsink LM, et al. The gut-renal axis: do incretin-based agents confer renoprotection in diabetes? Nat Rev Nephrol 2014;10:88-103.
    • (2014) Nat Rev Nephrol , vol.10 , pp. 88-103
    • Mha, M.1    Smits, M.M.2    Morsink, L.M.3
  • 41
    • 77955573674 scopus 로고    scopus 로고
    • Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): A randomised trial
    • Bergenstal RM, Wysham C, Macconell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010;376:431-9.
    • (2010) Lancet , vol.376 , pp. 431-439
    • Bergenstal, R.M.1    Wysham, C.2    Macconell, L.3
  • 44
    • 84890476805 scopus 로고    scopus 로고
    • Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction
    • Groop P-H, Cooper ME, Perkovic V, et al. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care 2013;36:3460-8.
    • (2013) Diabetes Care , vol.36 , pp. 3460-3468
    • Groop, P.-H.1    Cooper, M.E.2    Perkovic, V.3
  • 45
    • 84942789301 scopus 로고    scopus 로고
    • Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus and moderate or severe renal impairment: Observations from the SAVOR-TIMI 53 trial
    • Udell JA, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 trial. Diabetes Care 2015;38:696-705.
    • (2015) Diabetes Care , vol.38 , pp. 696-705
    • Udell, J.A.1    Bhatt, D.L.2    Braunwald, E.3
  • 46
    • 84928601182 scopus 로고    scopus 로고
    • Pleiotropic effects of type 2 diabetes management strategies on renal risk factors
    • Muskiet MHA, Tonneijck L, Smits MM, et al. Pleiotropic effects of type 2 diabetes management strategies on renal risk factors. Lancet Diabetes Endocrinol 2015;3:367-81.
    • (2015) Lancet Diabetes Endocrinol , vol.3 , pp. 367-381
    • Mha, M.1    Tonneijck, L.2    Smits, M.M.3
  • 47
    • 72449157026 scopus 로고    scopus 로고
    • Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas
    • Nachnani JS, Bulchandani DG, Nookala A, et al. Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia 2010;53:153-9.
    • (2010) Diabetologia , vol.53 , pp. 153-159
    • Nachnani, J.S.1    Bulchandani, D.G.2    Nookala, A.3
  • 48
    • 72449148137 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 therapy and the exocrine pancreas: Innocent bystander or friendly fire?
    • Butler PC, Matveyenko AV, Dry S, et al. Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire? Diabetologia 2010;53:1-6.
    • (2010) Diabetologia , vol.53 , pp. 1-6
    • Butler, P.C.1    Matveyenko, A.V.2    Dry, S.3
  • 49
    • 84930629862 scopus 로고    scopus 로고
    • Incretin-based therapy and risk of acute pancreatitis: A Nationwide Population-Based Case-Control Study
    • Thomsen RW, Pedersen L, Møller N, et al. Incretin-based therapy and risk of acute pancreatitis: a Nationwide Population-Based Case-Control Study. Diabetes Care 2015;38:1089-98.
    • (2015) Diabetes Care , vol.38 , pp. 1089-1098
    • Thomsen, R.W.1    Pedersen, L.2    Møller, N.3
  • 50
    • 84896731936 scopus 로고    scopus 로고
    • Pancreatic safety of incretin-based drugs-FDA and EMA assessment
    • Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs-FDA and EMA assessment. N Engl J Med 2014;370:794-7.
    • (2014) N Engl J Med , vol.370 , pp. 794-797
    • Egan, A.G.1    Blind, E.2    Dunder, K.3
  • 51
    • 84918828271 scopus 로고    scopus 로고
    • Chronic continuous exenatide infusion does not cause pancreatic inflammation and ductal hyperplasia in non-human primates
    • Fiorentino TV, Owston M, Abrahamian G, et al. Chronic continuous exenatide infusion does not cause pancreatic inflammation and ductal hyperplasia in non-human primates. Am J Pathol 2015;185:139-50.
    • (2015) Am J Pathol , vol.185 , pp. 139-150
    • Fiorentino, T.V.1    Owston, M.2    Abrahamian, G.3
  • 52
    • 0037667613 scopus 로고    scopus 로고
    • Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes
    • Meier JJ, Gallwitz B, Salmen S, et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 2003;88:2719-25.
    • (2003) J Clin Endocrinol Metab , vol.88 , pp. 2719-2725
    • Meier, J.J.1    Gallwitz, B.2    Salmen, S.3
  • 53
    • 84956914555 scopus 로고    scopus 로고
    • Incretin-based therapies for the treatment of nonalcoholic fatty liver disease: A systematic review and meta-analysis
    • Published Online First: 25 June 2015
    • Carbone LJ, Angus PW, Yeomans ND. Incretin-based therapies for the treatment of nonalcoholic fatty liver disease: a systematic review and meta-analysis. J Gastroenterol Hepatol 2015. Published Online First: 25 June 2015. doi:10.1111/jgh.13026
    • J Gastroenterol Hepatol 2015
    • Carbone, L.J.1    Angus, P.W.2    Yeomans, N.D.3
  • 54
    • 57649166909 scopus 로고    scopus 로고
    • Clinical trial: The glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: A randomized, placebo-controlled, double-blind study
    • Hellström PM, Hein J, Bytzer P, et al. Clinical trial: the glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study. Aliment Pharmacol Ther 2009;29:198-206.
    • (2009) Aliment Pharmacol Ther , vol.29 , pp. 198-206
    • Hellström, P.M.1    Hein, J.2    Bytzer, P.3
  • 55
    • 80052812653 scopus 로고    scopus 로고
    • Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function
    • Marathe CS, Rayner CK, Jones KL, et al. Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function. Exp Diabetes Res 2011;2011:279530.
    • (2011) Exp Diabetes Res , vol.2011 , pp. 279530
    • Marathe, C.S.1    Rayner, C.K.2    Jones, K.L.3
  • 56
    • 0027533758 scopus 로고
    • Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man
    • Wettergren A, Schjoldager B, Mortensen PE, et al. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993;38:665-73.
    • (1993) Dig Dis Sci , vol.38 , pp. 665-673
    • Wettergren, A.1    Schjoldager, B.2    Mortensen, P.E.3
  • 57
    • 0030962231 scopus 로고    scopus 로고
    • The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation
    • Wettergren A, Wojdemann M, Meisner S, et al. The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation. Gut 1997;40:597-601.
    • (1997) Gut , vol.40 , pp. 597-601
    • Wettergren, A.1    Wojdemann, M.2    Meisner, S.3
  • 58
    • 0024338802 scopus 로고
    • GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans
    • Schjoldager BT, Mortensen PE, Christiansen J, et al. GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans. Dig Dis Sci 1989;34:703-8.
    • (1989) Dig Dis Sci , vol.34 , pp. 703-708
    • Schjoldager, B.T.1    Mortensen, P.E.2    Christiansen, J.3
  • 59
    • 84866701959 scopus 로고    scopus 로고
    • Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects
    • Keller J, Trautmann ME, Haber H, et al. Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects. Regul Pept 2012;179:77-83.
    • (2012) Regul Pept , vol.179 , pp. 77-83
    • Keller, J.1    Trautmann, M.E.2    Haber, H.3
  • 60
    • 84871564295 scopus 로고    scopus 로고
    • Direct effect of GLP-1 infusion on endogenous glucose production in humans
    • Seghieri M, Rebelos E, Gastaldelli A, et al. Direct effect of GLP-1 infusion on endogenous glucose production in humans. Diabetologia 2013;56:156-61.
    • (2013) Diabetologia , vol.56 , pp. 156-161
    • Seghieri, M.1    Rebelos, E.2    Gastaldelli, A.3
  • 61
    • 27744541052 scopus 로고    scopus 로고
    • Exenatide augments first-and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes
    • Fehse F, Trautmann M, Holst JJ, et al. Exenatide augments first-and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2005;90:5991-7.
    • (2005) J Clin Endocrinol Metab , vol.90 , pp. 5991-5997
    • Fehse, F.1    Trautmann, M.2    Holst, J.J.3
  • 62
    • 78650507366 scopus 로고    scopus 로고
    • GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons
    • Griffioen KJ, Wan R, Okun E, et al. GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons. Cardiovasc Res 2011;89:72-8.
    • (2011) Cardiovasc Res , vol.89 , pp. 72-78
    • Griffioen, K.J.1    Wan, R.2    Okun, E.3
  • 63
    • 2942668372 scopus 로고    scopus 로고
    • Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men
    • Gutzwiller J-P, Tschopp S, Bock A, et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 2004;89:3055-61.
    • (2004) J Clin Endocrinol Metab , vol.89 , pp. 3055-3061
    • Gutzwiller, J.-P.1    Tschopp, S.2    Bock, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.